Market News

Edesa (NASDAQ:EDSA) Rises on Promising Phase 2 ARDS Results

Edesa Biotech (NASDAQ:EDSA) shares are on the rise today on the back of promising results from the Phase 2 part of its Phase 2/ Phase 3 study evaluating Edesa’s EB05 candidate for the treatment of hospitalized patients that may or may not be at risk of COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).

The treatment showed a statistically significant and clinically meaningful trend for mortality and survival time. Further, a revised analysis indicated EB05 plus standard of care delivered an 84% reduction in mortality risk versus placebo.

Edesa’s Phase 3 study design for the treatment has already received approval in Canada, Colombia, and Poland and is under review in the U.S.

Is EDSA Stock a Buy?

The Street remains cautiously optimistic about Edesa stock at present with a Moderate Buy consensus rating.

While EDSA stock has not been assigned a target price by analysts yet, a beta of 3.14 means the stock can gyrate more than the broader market, and caution is warranted.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More